Advancing Automation in Drug Development
Eli Lilly Unveils $250M LillyPod AI Supercomputer
The drugmaker aims to automate complex chemical discovery and predict the 'language of medicines' via AI.
A high-tech server room with rows of glowing blue supercomputer racks in a clean, modern pharmaceutical research facility.
Photo: Kronos Digital News
Eli Lilly and Co. has launched a $250 million AI supercomputer named LillyPod to transform its research capabilities [1]. The pharmaceutical company designed the system to predict what executives call the "language of medicines" [1]. This technology helps automate complex steps in chemical invention and drug development [1].
Executives are increasing investments in artificial intelligence to accelerate the discovery of new treatments [1]. The LillyPod system represents a significant shift toward digital transformation in the pharmaceutical industry [1]. By using AI, the firm aims to shorten the timeline for bringing new drugs to market [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
The story relies on a single source from the Indianapolis Business Journal.
Sources
Related stories
View all
Topics
About the author
Kronos Digital News Desk covers advancing automation in drug development and editorial analysis for Kronos Digital News.